Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer

Navitski, A., Al-Rawi, D. H., Liu, Y., Rubinstein, M. M., Friedman, C. F., Rampal, R. K., Mandelker, D. L., Cadoo, K., & O’Cearbhaill, R. E. (2021). Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer. Gynecologic Oncology Reports, 38, 100873. https://doi.org/10.1016/j.gore.2021.100873

Authors:

Anastasia Navitski

Duaa H Al-Rawi

Ying Liu

Maria M Rubinstein

Claire F Friedman

Raajit K Rampal

Diana L Mandelker

Karen Cadoo

Roisin E O'Cearbhaill

Affiliated Authors:

Anastasia Navitski